Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - zapalenie stawów, reumatoidalne - leki immunosupresyjne - kevzara w skojarzeniu z metotreksatem (mtx) jest wskazany w leczeniu umiarkowanej do ciężkiej, czynnej reumatoidalne zapalenie stawów (ra) u dorosłych pacjentów, którzy odpowiedzieli nieodpowiednio do, lub którzy tolerują jedną lub więcej chorobą modyfikowanie anty reumatyczne leków (dmards). preparat kevzara można podawać w monoterapii w przypadku nietolerancji mtx lub gdy leczenie mtx jest nieodpowiednie.

Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - leki immunosupresyjne - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi b.v. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation; lymphoma - Иммуностимуляторы, - produkt leczniczy mozobil w skojarzeniu z czynnik stymulujący kolonie granulocytów do zwiększenia mobilizacja komórek macierzystych krwi do krwi obwodowej do kolekcji i kolejnych autologicznych transplantacji u chorych na chłoniaka i szpiczaka szpiczaka mnogiego, których komórki zmobilizować słabo.

Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Środki do zapalenia skóry, z wyłączeniem kortykosteroidy - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - denga - szczepionki - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 i 4. korzystanie z dengvaxia powinny być zgodne z oficjalnymi zaleceniami.

Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi winthrop industrie - insulina glargine, lixisenatide - diabetes mellitus, type 2 - leki stosowane w cukrzycy - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - szczepionka hexacima (dtap-ipv-hb-hib) jest wskazana do szczepienia pierwotnego i uzupełniającego niemowląt i małych dzieci od szóstego tygodnia życia przeciw błonicy, tężcowi, krztuścowi, wirusowemu zapaleniu wątroby typu b, poliomyelitis i inwazyjne choroby wywołane przez haemophilus influenzae typu b (hib). stosowanie tej szczepionki powinno odbywać się zgodnie z oficjalnymi zaleceniami.

Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - szczepionki - szczepionka hexyon (dtap-ipv-hb-hib) jest wskazana do szczepienia pierwotnego i uzupełniającego niemowląt i małych dzieci od szóstego tygodnia życia przeciw błonicy, tężcowi, krztuścowi, wirusowemu zapaleniu wątroby typu b, poliomyelitis i inwazyjne choroby wywołane przez haemophilus influenzae typu b (hib). stosowanie tej szczepionki powinno odbywać się zgodnie z oficjalnymi zaleceniami.

Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi winthrop industrie - insulina aspart - cukrzyca - leki stosowane w cukrzycy - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

Evrópusambandið - pólska - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - szczepionki - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 i 5. 1 in product information document). stosowanie tej szczepionki powinno odbywać się zgodnie z oficjalnymi zaleceniami.